GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Ibere Pharmaceuticals (NYSE:IBER.U) » Definitions » Additional Paid-In Capital

IBER.U (Ibere Pharmaceuticals) Additional Paid-In Capital : $0.00 Mil(As of Sep. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Ibere Pharmaceuticals Additional Paid-In Capital?


Ibere Pharmaceuticals's annual additional paid-in capital increased from . 20 ($0.00 Mil) to Dec. 2020 ($0.03 Mil) but then declined from Dec. 2020 ($0.03 Mil) to Dec. 2021 ($0.00 Mil).

Ibere Pharmaceuticals Additional Paid-In Capital Historical Data

The historical data trend for Ibere Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ibere Pharmaceuticals Additional Paid-In Capital Chart

Ibere Pharmaceuticals Annual Data
Trend Dec20 Dec21
Additional Paid-In Capital
0.03 -

Ibere Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Additional Paid-In Capital Get a 7-Day Free Trial - - - - -

Ibere Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Ibere Pharmaceuticals Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Ibere Pharmaceuticals's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Ibere Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Ibere Pharmaceuticals (NYSE:IBER.U) » Definitions » Additional Paid-In Capital
Comparable Companies
MEPW UOLI JATT APCA ITAQ MURF WAYS LJAQ DMAQ NMMC GSHN PSTH XAMS:EPIC ASZ CCYC CVII KAHC DWAC IPOF PBAJ
Traded in Other Exchanges
N/A
Address
2005 Market Street, Suite 2030, Philadelphia, PA, USA, 19103
Website
https://www.iberepharma.com
Ibere Pharmaceuticals is a blank check company.
Executives
Elaine V Jones director C/O TARGACEPT, INC., 200 EAST FIRST STREET, SUITE 300, WINSTON-SALEM NC 27101
Osagie O Imasogie director, 10 percent owner, officer: Chief Executive Officer
Calvin B. Johnson director 2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Zoltan Kerekes director, 10 percent owner, officer: Chief Operating Officer 2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Louis J. Vollmer director 2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Lisa M. Gray director, 10 percent owner, officer: Chief Financial Officer 2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Henrietta Ukwu director 2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103
Pipv Capital Llc 10 percent owner 2005 MARKET STREET, SUITE 2030, PHILADELPHIA PA 19103

Ibere Pharmaceuticals Headlines

From GuruFocus

Ibere Pharmaceuticals Receives Expected NYSE Notice Regarding Delayed Quarterly Report

By PRNewswire PRNewswire • 05-28-2021

Ibere Pharmaceuticals Announces Closing of $138,000,000 Initial Public Offering

By PRNewswire PRNewswire • 03-03-2021